SUMMARY Platelet activation, which results in release of the platelet-specific proteins platelet factor 4 (PF4) and BTG thromboglobulin (BTG), may participate in exercise-induced myocardial ischemia by the formation of intravascular platelet aggregates or the generation of vasoactive substances such as thromboxane A2. We sought to determine if platelet release occurs during exercise-induced ntyocardial ischemia and its relationship to exercise-induced catecholamine release in 10 normal males (mean age 29 + 6 years) and 25 males with proved coronary artery disease (mean age 60 ± 8 years) who performed maximal, symptomlimited treadmill exercise tests. None of the subjects took drugs known to modify platelet behavior; 17 coronary artery disease patients took B-blocking agents. Plasma and urine PF4, plasma BTG and plasma catecholamines were measured before and immediately after exercise. Plasma PF4 and BTG were also measured 30 minutes after exercise. Ischemia, defined as angina or 1 mm or more of horizontal or downsloping ST depression, developed in 14 coronary artery disease patients.
ence of these proteins in plasma has been proposed as a measure of in vivo platelet release in a variety of disease states."'7 Studies of platelet a-granule release during exercise have been inconclusive. In coronary artery disease patients and in normal persons, no changet or an increase in plasma PF4'9 20 or BTG21 22 during exercise have been reported. The divergent results in these and other studies of PF4 and BTG release have been attributed to methodologic differences.'6'8 Specimen collection and processing are of primary importance in ensuring that in vitro release of PF4 and BTG is minimized. 16-18 23 In the current study, we used a method for specimen handling and processing that has been documented to minimize in vitro platelet a granule release of PF4 and BTG. 7 Kaplan'6 suggested that the simultaneous measurement of both plasma PF4 and BTG may be particularly useful in discriminating between in vitro and in vivo release; release in vitro would be expected to equally elevate plasma PF4 and BTG, while release in vivo might disproportionately elevate BTG because of its slower plasma clearance. 33 VOL 66, No 1, JULY 1982 The purpose of this study was to determine whether PF4 or BTG release occurs during maximal upright treadmill exercise in normal subjects or in patients with proved coronary artery disease, and to relate any changes to evidence of exercise-induced myocardial ischemia or exercise-induced catecholamine release. We also assessed the time course of PF4 release in normal subjects during maximal supine bicycle exercise, since repeat venipunctures cannot be readily performed during upright treadmill testing. To explain the exercise-related elevations of platelet-specific proteins found in other studies, we also assessed whether repeated venipunctures from the same site or serial sampling from an indwelling venous catheter artifactually elevated plasma PF4 levels.
Methods

Subjects
Ten normal male volunteers (mean age 29 + 6 years, range 24-44 years) with no history or physical findings of cardiovascular disease were studied. Nine had normal resting ECGs; one had preexcitation. None had taken any medications, including platelet-active drugs (aspirin-containing compounds, dipyridamole, sulfinpyrazone or other nonsteroidal antiinflammatory drugs), within 1 week of the study. Young normal volunteers were studied because they could be assumed to be free of coronary artery disease. No control patients in the older age range were studied.
Twenty-five males (mean age 60 ± 8 years, range 46-74 years) with clinically stable coronary artery disease were selected for study from a cardiovascular disease clinic. Sixteen had symptomatic angina pectoris and coronary artery disease (D 70% diameter reduction of at least one vessel) proved at catheterization; the other nine patients had sustained a remote myocardial infarction. Overall, 19 of the 25 patients had prior infarction, 14 transmural and five nontransmural. No patient had sustained a myocardial infarction within 3 months of the time of study. Myocardial infarction was documented by new electrocardiographic Q waves, ST-T changes or both, as well as an appropriate clinical history and elevation of creatine kinase to more than twice the normal level. Nineteen patients had a history of angina pectoris within 1 month before study. Five (patients 11, 12, 21, 33, 34 in table 1) had undergone coronary artery bypass grafting, four of whom had recurrent angina. No patient had received platelet-active drugs for at least 1 week before study. Sixteen patients were taking propranolol (mean dose 221 ± 209 mg/day, range 40-800 mg/day) and one patient was taking metoprolol (100 mg/day). Patients 22 and 24 (table 1) were taking digoxin (0.25 mg/day). Ten patients were taking long-acting nitrates. All subjects were informed of the investigational nature of the study and gave informed consent. For supine bicycle exercise testing, our previously described protocol was performed in four additional young normal subjects . 25 The subject pedaled a bicycle ergometer in the supine position for 4-minute stages, beginning at 200 kilopond-meters (kpm)/min and increasing by 200 kpm/min until reaching a symptomlimited maximum.
Specimen Collection and Assay
For upright treadmill exercise tests, blood specimens for plasma PF4, BTG and catecholamine determinations were collected in all 35 subjects immediately before exercise with the subject sitting and within 1 minute of stopping exercise with the subject either sitting or supine. Thirty minutes after exercise, specimens were also collected for plasma PF4 and BTG in 29 subjects, six normal and 23 with coronary disease. Pre-and postexercise urine specimens for urine PF4 were collected in 33 subjects (10 normal and 23 with coronary disease).
During the four supine bicycle exercise tests, all subjects had an indwelling i.v. catheter in the right arm for plasma catecholamine sampling. Saline without heparin was used to keep this catheter open. Samples for plasma PF4 and BTG measurement were drawn from separate venipunctures in the opposite arm at supine rest, during the tenth minute of exercise, immediately after exercise and at 30 minutes after exercise.
Our methods of specimen collection and processing for plasma and urine PF4 and plasma ITG have been previously described."7 At each sampling time, duplicate blood samples were collected by a single venipuncture with a 21-gauge butterfly needle into 5-ml syringes that were precooled in ice and contained 1 3042 ±1357* venous blood were drawn at rest and at maximal exercise and placed into prechilled glass tubes containing heparin and glutathione (5 mmol/l final concentration), which were immediately placed on ice. A singleisotope radioenzymatic assay was performed as previously described. 26 The mean basal supine level in 95 normal subjects using this method was 252 + 138 pg/ ml for norepinephrine and 50 ± 22 pg/ml for epinephrine in this laboratory.
Statistical Analysis
The data were evaluated using Wilcoxon's signedrank test for paired data and the Mann-Whitney test for unpaired data. Results are expressed as mean ± SD. Clinical data and plasma PF4 and BTG responses for all 35 subjects undergoing upright treadmill testing are presented in table 1. In normal subjects, mean plasma PF4 was 2.1 ± 1.2 ng/ml at rest, increased to 4.7 + 2.6 ng/ml at peak exercise (p < 0.01 vs rest), and fell to 2.5 ± 1.5 ng/ml at 30 minutes after exercise (NS vs rest) (figs. 1 and 2). Among the 11 coronary artery disease patients without exercise-induced ischemia, plasma PF4 was 1.6 ± 0.5 ng/ml at rest, 2.2 ± 0.9 ng/ ml at peak exercise, and 3.1 ± 4.5 ng/ml at 30 minutes after exercise (both NS vs rest) ( fig. 2, table 2 ). Peak exercise plasma PF4 was minimally but significantly greater in normal subjects than in the 11 coronary artery disease patients without exercise-induced ischemia (p < 0.01).
Among the 14 coronary artery disease patients who developed evidence of myocardial ischemia during exercise (angina or ST depression), plasma PF4 was 2.6 ± 1.7 ng/ml at rest, 3 .0 + 2.9 ng/ml at peak exercise, and 4.3 + 4.3 ng/ml at 30 minutes after exercise (both NS vs rest) (figs. 1 and 2). The mean rest, exercise and 30-minute postexercise plasma PF4 values in the 14 patients with exercise-induced ischemia did not differ significantly from the corresponding values in normal subjects or from the values in the 11 coronary artery disease patients without exercise-induced ischemia (table 2). The increase in plasma PF4 from rest to peak exercise was significantly less in coronary artery disease patients with exercise-induced ischemia (0.4 + 2.5 ng/ml) than in normal subjects (2.6 ± 2.2 ng/ml;p < 0.05), but not different from that in coronary artery disease patients without exercise-induced ischemia (0.6 ± 0.6 ng/ml; NS). The increase in plasma PF4 from rest to 30 minutes after exercise was not signifi-37 VOL 66, No 1, JULY 1982 cantly different between coronary artery disease patients with ischemia (1.7 ± 4.6 ng/ml) and normal subjects (0.4 ± 2.2 ng/ml) and coronary artery disease patients without ischemia (1.5 ± 4.6 ng/ml) (both NS).
When all 25 coronary artery disease patients are considered together, plasma PF4 was 2.1 ± 1.4 ng/ml at rest, 2.6 ± 2.2 ng/ml at peak exercise (p < 0.01 vs rest) and 3.8 ± 4.3 ng/ml at 30 minutes after exercise (NS vs rest). The exercise-induced increase in plasma PF4 among all 25 coronary artery disease patients (0.5 ± 1.9 ng/ml) was significantly less than that in normal subjects (2.6 ± 2.2 ng/ml; p < 0.01).
Among normal subjects, mean plasma BTG was 11.7 ± 5.4 ng/ml at rest, 16.7 ± 7.7 ng/ml at peak exercise (p < 0.01 vs rest) and 12.8 ± 3.9 ng/ml at 30 minutes after exercise (NS vs rest) ( fig. 3) . Among the 11 coronary artery disease patients who did not develop exercise-induced ischemia, plasma BTG was 12.9 ± 5.6 ng/ml at rest, 14.0 ± 3.8 ng/ml at peak exercise, and 14.8 ± 5.8 ng/ml at 30 minutes after exercise (both NS vs rest). Among the 14 coronary artery disease patients who developed exercise-induced ischemia, plasma BTG was 13.6 ± 6.4 ng/ml at rest, 14.1 ± 7.1 ng/ml at peak exercise and 16.9 ± 6.5 ng/ml at 30 minutes after exercise (both NS vs rest). The increase in plasma BTG from rest to peak exercise in the 14 patients with exercise-induced ischemia (0.5 ± 3.4 ng/ml) and the 11 coronary disease patients without exercise-induced ischemia (1.1 ± 2.9 ng/ml) was significantly less than the increase in normal subjects (5.0 ± 4.1 ng/ml; both p < 0.05). When all 25 coronary artery disease patients are considered together, plasma BTG was 13.3 ± 6.0 ng/ml at rest, 14.1 ± 5.8 ng/ml at peak exercise, and 16.0 ± 6.2 ng/ml 30 minutes after exercise (both NS vs rest). The increase in plasma BTG from rest to exercise in all patients with coronary artery disease (0.8 ± 3.1 ng/ml) was significantly less than that in normal subjects (5.0 ± 4.1 ng/ml; p < 0.01). Additionally, the five coronary artery disease patients who developed two manifestations of ischemia during exercise (both angina and ST depression) did not have significantly higher plasma PF4 or 1BTG responses at peak exercise than either normal subjects or the other 20 coronary artery disease patients (table 2) . Rest, exercise and postexercise plasma PF4 and BTG levels were not significantly different between the 17 coronary artery disease patients taking 3 blockers and the eight coronary artery disease patients not taking B blockers (table 2, fig. 4 ). At rest, plasma PF4 was 2.0 ± 1.0 ng/ml in the 17 coronary artery disease patients taking B blockers and was 2.5 ± 1.9 ng/ml in the eight coronary disease patients not taking B blockers (NS). At peak exercise, plasma PF4 was 2.9 ± 2.7 ng/ml in patients taking B blockers and was 2.0 ± 0.6 ng/ml in patients not taking B blockers (NS). Plasma BTG at rest was 14.1 + 6.3 ng/ml in patients taking B blockers and 11.8 ± 5.4 ng/ml in patients not taking B blockers (NS). At peak exercise, plasma BTG was 14.8 + 6.7 in patients taking B blockers and 12.5 ± 2.9 ng/ml in patients not taking B blockers (NS). Plasma PF4 and BTG levels 30 minutes after exercise in the two groups were also not significantly different ( line to exercise in any subject group (all NS) (table 2) . Among all 35 patients, there was a highly significant correlation between change in plasma PF4 and change in plasma BTG from rest to peak exercise (r = 0.70, p < 0.001). There was also a significant correlation between all rest and exercise PF4 and BTG values (r = 0.62, p < 0.001) in all 35 subjects. Patient 2, the young normal subject who showed the greatest change in plasma PF4 during treadmill exercise, underwent repeat maximal exercise testing on a different day. On initial testing, plasma PF4 increased from 1.7 to 8.6 ng/ml and on repeat testing plasma PF4 increased from 3.5 to 8.8 ng/ml, suggesting that exercise-induced increases in plasma PF4 were reproducible.
Plasma Epinephrine and Norepinephrine During Treadmill Exercise
Mean plasma epinephrine and norepinephrine levels at rest and exercise among normal subjects and coronary artery disease subgroups are presented in table 2 and figure 5. Resting plasma norepinephrine was higher among all 25 coronary artery disease patients than normal subjects (692 + 283 vs 394 ± 122 pg/ml, p < 0.001), which is probably related to differences in age and in B-blockade therapy between the two groups. Exercise norepinephrine was higher in normal subjects (3823 ± 1233 vs 2607 ± 1740 pg/ml, p < 0.05). Resting epinephrine was not significantly different between groups, but normal subjects had higher exercise epinephrine levels than coronary artery disease patients (653 ± 367 vs 264 ± 178 pg/ml, p < 0.001).
The 14 coronary artery disease patients with exercise-induced ischemia did not have rest or exercise catecholamine levels significantly different from those in the 11 coronary artery disease patients without exercise-induced ischemia (table 2). Epinephrine increased from 85 ± 33 to 272 ± 201 pg/ml in patients with exercise-induced ischemia and from 78 ± 45 to 250 + 152 pg/ml in patients without ischemia (NS, patients with ischemia vs patients without ischemia). Norepinephrine increased from 698 ± 239 to 2853 ± 2051 pg/ml in patients with ischemia and from 683 ± 342 to 2293 ± 1268 pg/ml in patients without ischemia (NS).
Among all 35 subjects, there was a correlation between the increase in plasma epinephrine from rest to exercise and the increase in plasma PF4 (r = 0.35, p = 0.04) and BTG (r = 0.40 p = 0.02). There was no correlation between exercise changes in plasma norepinephrine and PF4 (r = 0.24; p = 0.2) orBTG (r = 0. 23;p= 0.2).
Plasma PF4, BTG and Catecholamine Levels During Supine Bicycle Exercise Changes in plasma PF4, BTG and catecholamine levels with moderate and maximal supine bicycle testing in four normal subjects are listed in table 3 and figure 6. Mean duration was 19 ± 3 minutes (range 16-22 minutes). Mean plasma PF4 increased from 1.2 ± 0.3 ng/ml at rest to 1.6 ± 0.3 ng/ml during the tenth minute of exercise (NS vs rest) and to 2.1 ± 0.7 ng/ml at maximal exercise (p < 0.05 vs rest) ( fig. 6 ). Corresponding mean plasma BTG levels were 18.8 ± 9.6, 14.0 ± 4.9 and 15.8 ± 5.4 ng/ml (all NS, rest vs exercise). Increases in plasma PF4 occurred at the time of maximal increases in plasma catecholamines. Exercise plasma catecholamine levels were lower in the supine protocol, as were maximal plasma PF4 and BTG responses in this small group. There was no change in urine PF4 during supine exercise. Abbreviations: Max = maximal exercise; 30 min = 30 minutes after completion of exercise; ND = not done; PF4 = platelet factor 4; fTG =, thromboglobulin.
time of catheter placement and 15 and 30 minutes later were 2.0 + 0.4, 6.9 + 3.4, and 7.8 ± 3.6 ng/ml, respectively ( fig. 7) . The 15-and 30-minute samples were significantly elevated from baseline (both p < 0.05 vs baseline).
Mean plasma PF4 values obtained by repeated, separate venipunctures every 15 minutes from the same venous site in four normal subjects showed no statistically significant elevations in this small sample (2.9 + 1.7, 1.8 ± 0.9, 3.8 ± 3.2 and 1.8 ± 0.7 ng/ml, respectively). However, two of the four patients had elevations of plasma PF4 greater than 1 ng/ml on repeated sampling, one from 2.5 to 3.6 ng/ml and one from 5.4 to 8.5 ng/ml. Discussion Abnormal platelet activation, as evidenced by exercise-induced elevations in plasma PF4 or BTG, was not detected during exercise-induced myocardial ischemia in patients with proved coronary artery disease. In contrast, the 10 normal control subjects had exerciseinduced increases in both plasma PF4 and BTG that exceeded those in the 14 coronary artery disease patients with exercise-induced ischemia. The exerciseinduced increases in normal subjects were also greater than the small increases seen in the entire group of 25 coronary artery disease patients. There were no differences in plasma PF4 or 13TG responses between the 17 coronary artery disease patients taking B blockers and the eight coronary artery disease patients not taking B blockers. Thus, it is unlikely that the lack of elevation of plasma PF4 or BTG in coronary artery disease patients with exercise-induced myocardial ischemia was due to B blocker therapy. In fact, the 17 patients taking B blockers had a small but statistically significant increase in plasma PF4, but not in BTG from rest to peak exercise. Among the three coronary artery disease subjects not taking B blockers who developed exerciseinduced ischemia, mean plasma PF4 actually fell from rest to peak exercise. Lindenfeld Rest  10 min  Max  30  80  550  610  800  1710  70  40  140  265  430  600  30  50  1240  250  420  4000  60  100  180  400  670  1060  33  68  528  381  580  1842  +21 +28* +510* ±167 ±187* ±1509: difference in plasma PF4 response to exercise before and after propranolol therapy in both patients with angina and in normal subjects. Thus, propranolol therapy does not appear to significantly influence plasma PF4 responses to exercise. The lack of an exercise increase in plasma PF4 or BTG in patients with exercise-induced ischemia also cannot be attributed to platelet-active drugs, since none of the subjects had taken any platelet-active medications for at least 1 week before testing. Prior coronary artery bypass surgery did not appear to influence the results; the five patients with prior surgery had similar results to the 20 coronary artery disease patients -without prior surgery. However, four of these patients had recurrent postoperative angina and were, therefore, not representative of all patients having coronary artery bypass grafting. Thus, we cannot attribute the lack of an exercise'rise in plasma PF4 and BTG in patients with proved coronary artery disease and exercise-induced ischemia to either B-blockade therapy, antiplatelet drug therapy, or prior coronary artery bypass grafting. Our results support the conclusion that exercise-induced myocardial ischemia does not produce platelet a' granule release that is detectable in peripheral venous blood or in urine.
Our results are in agreement with the findings of Mathis et al. , 18 who found exercise elevations of plasma PF4 above baseline levels in two of six normal subjects but in none of 11 patients with proved coronary artery disease. In contrast, Green and co-workers'9 reported that 11 of 20 patients (55%) with exercise ST depression had a greater than 50% increase in exercise plasma PF4, while only two of 20 patients (10%) without ST depression had similar plasma PF4 elevations. Using their criteria of a 50% increase in PF4 during exercise, 70% (seven of 10) of our normal subjects had an abnormal exercise PF4 response, while only 24% (six of 25) of our coronary artery disease patients had an abnormal response. The difference between our results and those of Green et al. may be because of differences in patient populations and differences in methods. Our normal subjects were younger than those studied by Green et 1, JULY 1982 cause of the exercise-induced increase in plasma PF4 and 13TG in most of our normal subjects and in some patients with coronary artery disease is uncertain. In normal subjects, the increase in plasma BTG (5.0 ng/ ml) was greater than that in plasma PF4 (2.6 ng/ml); these plasma levels parallel the relative amounts of these proteins in platelets as measured in our laboratory. 17 Others have reported that because BTG and PF4 are cleared at different rates, a greater increase in plasma BTG might be helpful in discriminating between in vivo release (BTG preferentially elevated due to slower plasma clearance) and in vitro release (equivalent elevations of BTG and PF4). 13 16 In any event, the exercise increases in plasma PF4 and BTG noted in the current study are consistent with exercise-induced platelet activation and release in vivo. Part of the increases in plasma PF4 and 3TG may be secondary to repeated sampling from the same vein, as noted above. This may explain the rise in plasma PF4 values at 30 minutes after exercise in four of the 25 coronary artery disease patients and in one of the six normal subjects sampled at that time. Therefore, a different venipuncture site was used, whenever possible, for each sample.
Platelet activation during exercise may be related to exercise duration, as suggested by the serial rises in PF4 during supine bicycle exercise. However, among all 35 subjects who underwent upright treadmill testing, exercise duration did not correlate with changes in PF4 (r = 0.27, p = 0.1), but did correlate with changes in plasma BTG (r = 0.48, p -0.007). The lack of plasma BTG elevation in patients with coronary artery disease may be explained by this association, since these patients exercised significantly less than normal subjects.
Exercise changes in plasma PF4 and BTG may be partially related to increases in circulating epinephrine, as suggested by the finding that among all 35 subjects, changes in plasma epinephrine during upright treadmill testing correlated with changes in plasmaPF4(r = 0.35,p = 0.04)andBTG(r= 0.45,p -0.01). Platelets possess a-adrenergic receptors28 29 and the interaction of epinephrine with these receptors initiates platelet aggregation.28' 29 Alexander et al. 28 postulated that these receptors are regulated by changes in the circulating levels of a agonists. Kaplan et al. showed that epinephrine at supraphysiologic levels in vitro causes PF4 and BTG release. 15 Although epinephrine at physiologic levels does not cause platelet aggregation in vitro, it may enhance aggregation to other stimuli.30 In the current study, there were no significant differences in catecholamine, PF4 or BTG levels during exercise in coronary artery disease patients with exercise-induced ischemia compared with coronary patients without exercise-induced ischemia. Thus, increases in plasma PF4 and BTG during exercise may be related more to increases in epinephrine than to the presence of myocardial ischemia.
Regional sampling of PF4 or BTG across the coronary vascular bed using specialized nonthrombogenic for circulating platelet aggregates3' and thromboxane B232, 33 may reveal evidence of localized PF4 and BTG release during myocardial ischemia. However, the finding that increases in plasma PF4 and BTG in peripheral venous blood during exercise did not correlate with the development of myocardial ischemia makes these measurements of platelet ax-granule release of limited clinical value, either in individual patients or in groups, despite the suggestion that PF4 and BTG levels might offer noninvasive assessment of therapy.
